Funding for this research was provided by:
Eunice Kennedy Shriver National Institute of Child Health and Human Development (U54HD079125)
National Center for Advancing Translational Sciences (UL1 TR000002)
Text and Data Mining valid from 2020-04-22
Received: 13 January 2020
Accepted: 27 March 2020
First Online: 22 April 2020
Ethics approval and consent to participate
: This study was approved by the Institutional Review Board at the University of California, Davis. Informed written consent was obtained from the parent/legal guardian prior to participation, and assent was obtained from each participant. The authors assert that all procedures contributing to this work comply with the ethical standards of the relevant national and international committees on human experimentation and with the Helsinki Declaration of 1975, as revised in 2008.
: Not applicable
: AJT has received funding for the development and implementation of treatment outcome measures from Fulcrum Therapeutics and the Azrieli Foundation. FT has received funding from the Azrieli Foundation, Zynerba, and Asuragen, Inc., for studies in FXS. RH has received funding from Zynerba, Ovid, and the Azrieli Foundation for treatment studies in children and adults with FXS. She has also consulted with Zynerba and Fulcrum regarding treatment studies in FXS. LA has received funding for the development and implementation of treatment outcome measures from the F. Hoffmann-La Roche Ltd., Roche TCRC, Inc., Neuren Pharmaceuticals Ltd., Fulcrum Therapeutics, Azrieli Foundation, and LuMind IDSC Foundation.